The Company possesses an international innovative drug technology platform centered on novel anti-tumor immunotherapeutic products (next-generation CAR-T, in vivo CAR-T, etc.), with CAR technology and the globally pioneering scalable high-purity retrovirus vector technology as its core. Its product portfolio covers hematologic malignancies, solid tumors, and autoimmune diseases.